| Document |
Document Title |
|
WO/2015/069541A1 |
The present invention provides a compound of Formula I or hydrate thereof, useful for the treatment of diabetes.
|
|
WO/2015/066001A1 |
Methods and compositions are provided for identifying novel ligands for a protein target.
|
|
WO/2015/054148A1 |
Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11,...
|
|
WO/2015/024298A1 |
The present invention relates to a macrolide compound as shown by formula I and pharmaceutically acceptable salts thereof. The compound of the present invention is an antibacterial agent, and can be used to treat various bacterial and pr...
|
|
WO/2015/014261A1 |
The present invention discloses a macrolide compound or salt thereof, synthesis method, pharmaceutical composition, and application thereof. The present invention provides a method for preparing a macrolide compound 1, a macrolide compou...
|
|
WO/2015/014907A1 |
The present invention discloses a novel process for preparation of tulathromycin. The process uses fewer steps due to a more direct route without prior protection of functional groups of the compound of formula (I).
|
|
WO/2014/204104A1 |
Provided are a method of producing a compound in which a sugar of a glycoside is reduced or removed, and an extract, a pharmaceutical composition, and a food composition including the compound.
|
|
WO/2014/200363A1 |
The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
|
|
WO/2014/197703A1 |
Provided are compounds of formula I useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as d...
|
|
WO/2014/194503A1 |
Provided are compounds useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as described abov...
|
|
WO/2014/187364A1 |
The present invention relates to a preparation method of trihydroxyethyl rutoside. In the method, rutin is firstly prepared into 7-monohydroxyethyl rutoside in a content of greater than or equal to 98% by weight, and then 7-monohydroxyet...
|
|
WO/2014/187957A1 |
The present invention relates to new macrolide derivatives, in particular new tylosin derivatives of the formula (Ila), a pharmaceutical or veterinary composition comprising the derivatives; a method for preparation thereof; a method for...
|
|
WO/2014/185717A1 |
The present invention relates to a novel epothilone derivative having improved water solubility by glucosylation of epothilone, to a method for preparing an epothilone derivative, to a pharmaceutical composition containing the epothilone...
|
|
WO/2014/173957A2 |
A compound of formula (I) wherein R is a C9-23 polyunsaturated alkenyl group; X is SO3R3, SO2R3, PO3R3, PO2R3, COCHal3, or COOR3; R1 and R2 are each independently H, a C1-6 a iky I group optionally substituted with OH, C6-10 aryl group o...
|
|
WO/2014/165676A1 |
Provided are an amphotericin B (AmB) derivative with an improved therapeutic index over amphotericin B, pharmaceutical compositions comprising the AmB derivative, methods of making the AmB derivative and the pharmaceutical composition, a...
|
|
WO/2014/140699A1 |
The present invention relates to a novel process for the liberation of Erythromycin from Erythromycin salts such as Erythromycin thiocyanate using water as a solvent in presence of a base. Erythromycin obtained by process of the present ...
|
|
WO/2014/145210A1 |
The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side c...
|
|
WO/2014/131995A1 |
A method for the enzymatic synthesis of diosmetin derivatives of formula (III):
|
|
WO/2014/121590A1 |
Flavonoids compounds of formula (I) or isoflavonoids compounds of formula (II), useful for treatment of HCV diseases, are disclosed. In the compounds, R1 is selected from formula(III), formula(IV) or formula(V); R2, R3, R4, R5 are select...
|
|
WO/2014/114729A1 |
The present invention relates to a compound of the following formula (I) or to a salt, hydrate, or pharmaceutically acceptable solvate thereof, in which R is a monosaccharide or disaccharide residue. The hydroxyl functions of the monosac...
|
|
WO/2014/102315A1 |
The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof and their use as PDE4 inhibitors.
|
|
WO/2014/094404A1 |
Disclosed is an avermectin raw material, where the purity of avermectin B2a is ≥ 30%. Also disclosed is an avermectin pesticide. Same uses avermectin B2a as an active ingredient, while at the same time comprises at least one agronomica...
|
|
WO/2014/094405A1 |
Disclosed is a method for extraction and preparation of avermectin B2a. The method comprises: an avermectin fermentation solution is prepared into a dry mycelium and leached; a leach liquor is concentrated, and extraction agents such as ...
|
|
WO/2014/085958A1 |
The erythromycin derivatives of the present invention, i.e., hydrated crystals of erythromycin stearate, has low moisture absorption and good storage stability, and is suitable for preparing drugs for treating and preventing infectious d...
|
|
WO/2014/064731A1 |
A method of obtaining a rutin-rich extract from a plant and a rutin-rich extract of Uncaria elliptica thus obtained.
|
|
WO/2014/066318A1 |
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therape...
|
|
WO/2014/059436A1 |
Site-selective functionalization of Amphotericin B has been achieved by simply modifying the electronic nature of the reagents. A Hammett analysis is consistent with linking of this phenomenon to the Hammond postulate: electronic tuning ...
|
|
WO/2014/055297A1 |
The present invention provides a compound of Formula I:, or a pharmaceutically acceptable salt thereof.
|
|
WO/2014/049356A1 |
The invention provides novel antibiotics, pharmaceutical compositions containing them and their medical use, for example in the treatment or prevention of microbial infections. Provided are compounds of Formula I, pharmaceutically accept...
|
|
WO/2014/050894A1 |
The present invention provides the compound represented by formula (1) (in the formula: X1 and X2 each independently represent -OR1, -NR2R3, -CR4R5R6, or the like; R1, R2, R3, R4, R5, and R6 each independently represent a glycosyl group ...
|
|
WO/2014/019685A1 |
The present invention relates to novel Chartreusin analogues of formula (I), pharmaceutical compositions comprising the same and to their use for the treatment of cancer and other diseases.
|
|
WO/2014/016361A1 |
The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia Coli infections. Exemplary compounds are:
|
|
WO/2013/189237A1 |
Disclosed are a novel andrographolide derivative and analogue as well as a preparation method of the novel andrographolide derivative and analogue and an application to the treatment, the prevention and the relief on human viruses and ne...
|
|
WO/2013/191550A1 |
The invention relates to the field of chemical derivatization. In particular, it relates to modified aminoglycosides, such as antibiotics, and methods for producing them. Provided is a method for the regioselective diazotation of a desox...
|
|
WO/2013/186384A1 |
The invention provides semisynthetic N-substituted derivatives of the antifungal antibiotic Amphotericin B and water soluble salts and complexes, pharmaceutical compositions and plant and building treatment products comprising the deriva...
|
|
WO/2013/186546A1 |
Complexes The invention provides aprocess for the preparation of a complex of Amphotericin B with poly(glutamic acid), which comprises the steps of i) mixing Amphotericin B with poly(glutamic acid) in the presence of water to form an aqu...
|
|
WO/2013/170142A1 |
The present invention provides solid state forms of Fidaxomycin, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising one or more of the solid state forms of Fidaxomycin, and p...
|
|
WO/2013/155849A1 |
The present invention relates to the field of drug synthesis. Disclosed is a method for preparing 5,6,4'-trihydroxyflavone-7-0-D-glucuronic acid. The method for preparing 5,6,4'-trihydroxyflavone-7-0-D-glucuronic acid of the present inve...
|
|
WO/2013/149577A1 |
Provided in the present invention are novel key intermediates of Selamectin and the preparation method thereof. Also provided is a new synthesis process, using Doramectin as a starting material, and obtaining Selamectin via hydrogenation...
|
|
WO/2013/139344A1 |
3-O-Fucosyllactose is made by process which includes the hydrogenolysis of a new compound of the formula 1 wherein R1 and R2 are independently a group removable by hydrogenolysis, and R3 is a group removable by hydrogenolysis or H; or a ...
|
|
WO/2013/131270A1 |
Disclosed is a Scutellarin hydrate of formula C21H18O12·nH2O, wherein n is a number between 1.75-2.0. Also disclosed in the present invention is the preparation method and use thereof. The hydrate has good storage stability, and is suit...
|
|
WO/2013/132014A1 |
The invention provides semisynthetic derivatives of Nystatin A1, water soluble salts and complexes, pharmaceutical compositions and plant protection products comprising the derivatives and their use, as antifungal antibiotics (Formula 1a).
|
|
WO/2013/134415A1 |
The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and m...
|
|
WO/2013/112897A1 |
Compositions and methods for stabilizing biomolecules are disclosed. Specifically, the compositions include novel homopolymers or copolymers containing trehalose side chains conjugated to biomolecules. When such homopolymers or copolymer...
|
|
WO/2013/109927A2 |
It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide ("AMP") and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain...
|
|
WO/2013/100315A1 |
The present invention relates to a novel polyene compound similar to nystatin, method for preparing same, and an antifungal drug comprising the novel polyene compound as an active ingredient. Compared to nystatin comprising one sugar, NP...
|
|
WO/2013/092753A1 |
The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune ...
|
|
WO/2013/086621A1 |
The present document describes a method for extracting anthocyanin derivatives from a plant source. The method comprises the step of separating a homogenized extract of plant source in a polar acidified solvent for obtaining a residual s...
|
|
WO/2013/076169A1 |
The present invention relates to new macrolide derivatives, in particular new tylosin derivatives of the formula (I); a pharmaceutical or veterinary composition comprising the derivatives; a method for preparation thereof; a method for t...
|
|
WO/2013/059927A1 |
The present application relates to the compounds of formula I (I) as well as their use for inhibiting at least one of AKT-1, FAK and PKCα and in the treatment and/or prevention of metastatic diseases.
|
